Elanco Animal Health beats Q1 guidance as Zenrelia blockbuster and protein shift drive double-digit growth

Elanco Animal Health Incorporated has delivered a strong opening to the fiscal year, reporting a 10 per cent organic revenue growth on a constant currency basis. The results outperformed the company's guidance across revenue, adjusted EBITDA, and adjusted earnings per share, driven by a combination of price increases and volume gains. Management attributed the success to a 'no regrets' launch strategy for its innovation portfolio, which is now projected to contribute $1.2 billion in revenue by 2026.

The standout performer in the quarter was Zenrelia, which achieved blockbuster status over a trailing four-quarter period. U.S. veterinary clinic sell-in for March exceeded any previous month by 30 per cent, reflecting sharply rising global demand ahead of peak allergy season. While the U.S. Food and Drug Administration has requested additional data for potential label improvements, the company views this as pure upside for 2027 rather than an immediate headwind.

Growth in the U.S. Farm Animal segment rose by 15 per cent, fuelled by what management describes as a 'protein revolution' and favourable producer economics in cattle and poultry. This surge occurred despite lower herd counts, as producers remain profitable and shift consumption toward protein sources. The company expects this segment to normalise toward long-term algorithms following the outsized 13 per cent organic growth seen in the first quarter.

Market share expansion was also a key driver, with Credelio Quattro capturing significant ground to reach 53 per cent of broad spectrum dispensing sales within the 40 per cent of U.S. clinics currently carrying the product. International Pet Health grew by 9 per cent, led by Zenrelia's rapid share capture in Brazil, where it holds over 50 per cent of the JAK market, and in Japan, where it commands over 35 per cent.

To support its omnichannel strategy, Elanco has secured new distribution partnerships with major retailers Costco and Dollar General. These alliances have driven high single-digit consumption growth in U.S. retail. The company also noted the official launch of Befrena this quarter and the continued ramp of corporate account contracts as primary drivers of its momentum.

Looking ahead, management has raised its full-year organic constant currency growth guidance to between 5 per cent and 7 per cent. The company anticipates meaningful gross margin expansion in the second half of 2026 as inventory cost headwinds subside and high-margin pet health revenue scales. Elanco also expects U.S. Pet Health to accelerate to high single-digit or low double-digit growth in the latter half of the year.